scholarly journals Squamous Cell Metastasis of Cancer from Cervix to Breast: A Case Report

2021 ◽  
Author(s):  
Luisa Paulina Chafla Romero ◽  
Karen Alejandra Venegas ópez ◽  
Erik Vinicio Bolaños Donoso ◽  
Lizbeth Katherine Valverde Franco ◽  
Jessica Monserrate Reinoso Mora
Keyword(s):  
Squamous Cell ◽  
Cell Cancer ◽  
Malignant Neoplasms ◽  
Second Line ◽  
Squamous Cells ◽  
Cell Metastasis ◽  
History Of ◽  
Frequent Site ◽  
Cancer Of The Cervix ◽  
Stage Ivb

Squamous cell metastasis from cervical cancer to breast is an extremely rare entity, approximately 29 cases have been documented worldwide since 1947 and it is the second documented case in Ecuador, the incidence is very low, it represents only 1,2 of all malignant neoplasms of the breast, which limits the expertise in the diagnosis and treatment of this metastasis, with the outermost quadrant of the breasts being the most frequent site of presentation. We present the clinical case of a 46-year-old married woman with a history of stage IVB squamous cell cancer of the cervix, who received chemotherapy, a Paclitaxel/Carboplatin regimen for 6 cycles. There was no good response and we had radiotherapy and brachytherapy treatment. The second line of chemotherapy with monodroga Gemcitab is proposed, the scheme is completed for 8 cycles. There is no favorable response, so a second-line chemotherapy treatment with Ifosfomide is proposed. The same metastases are present in the breast as after imaging and pathology examinations, it is concluded that the patient presents cervical Ca squamous cell metastases (cancer) from the cervix, 6 months after the diagnosis of the deceased patient. Metastasis to the breast from a neoplasm of other organs is very rare, the incidence of which is very low and the prognosis is gloomy. Keywords: metastasis, squamous cells, cancer of the cervix. RESUMEN La metástasis de células escamosas de cáncer de cérvix a mama es una entidad extremadamente rara, se ha documentado a nivel mundial aproximadamente 29 casos desde 1947 y es el segundo caso documentado en el Ecuador, la incidencia es muy baja, representa tan solo el 1,2 de todas las neoplasias malignas de la mama, lo que limita la experticia en el diagnóstico y tratamiento de esta metástasis, siendo el sitio más frecuente de presentación el cuadrante superior externo de las mamas. Se presenta el caso clínico de una paciente de 46 años, casada, con antecedentes de cáncer de cérvix de células escamosas en estadio IVB por lo que recibió tratamiento de quimioterapia, esquema Paclitaxel/Carboplatino por 6 ciclos. No hubo buena respuesta y recibió tratamiento de radioterapia y braquiterapia. Se propone segunda línea de quimioterapia con monodroga Gemcitab, se completa el esquema por 8 ciclos. No existió respuesta favorable por lo que se propone tratamiento de segunda línea de quimioterapia con Ifosfomida. Presenta metástasis en mama la misma que posterior a exámenes de imagen y patología se concluye que la paciente presenta metástasis de células escamosas de Ca (cáncer) de Cérvix a mama, 6 meses posterior al diagnóstico la paciente fallece. La metástasis en la mama de una neoplasia de otros órganos es muy raro cuya incidencia es muy baja y de pronóstico sombrío. Palabras claves: metástasis, células escamosas, cáncer de cérvix.

scholarly journals Squamous cell cancer of the cervix: prognostic factors related to survival

1991 ◽  
Vol 1 (4) ◽  
pp. 173-177 ◽  
Author(s):  
M. P. Hopkins ◽  
G. W. Morley
Keyword(s):  
Survival Rate ◽  
Lymph Nodes ◽  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Cell Cancer ◽  
Tumor Grade ◽  
Disease Stage ◽  
Stage Ia ◽  
Cancer Of The Cervix ◽  
Stage Ivb

Seven hundred and fifty-three patients with invasive squamous cell cancer of the cervix treated at the University of Michigan from 1970–1985 are reported. These included stage IA 43, stage IB 345, stage IIA 27, stage IIB 163, stage IIIA 4, stage IIIB 113, stage IVA 32, stage IVB 26. The age ranged from 18 to 92 years with a mean of 49.9 years. Clinical characteristics included: nulliparity 11%, married 93%, obese 41%, hypertensive 37%, diabetes 10%, smoking 50%, bleeding 76%. The cumulative five-year survival for all patients was 67% and this was influenced by the stage of disease: stage IA 98%, stage IB 89%, stage IIA 72%, stage IIB 62%, stage III 37%, stage IVA 14%, stage IVB 4%. Patients with a well-differentiated tumor had an 85% survival rate while those with a poorly differentiated tumor had a 57% survival rate. The probability of metastatic disease to lymph nodes corresponded to the stage of disease; stage I 17%, stage II 55%, stage III 70%, stage IV 81%. When lymph nodes were negative, the survival rate for all patients was 86% while those with positive nodes had a 33% survival rate. Factors which influenced survival in the univariate analysis included stage, node status, tumor grade, age, interval from previous pelvic examination, diabetes. Only stage, node status and tumor grade maintained significance in the multiple proportion hazard analysis.

Prolonged stabilization of progressive squamous cell cancer of the cervix with interferon-α and 13-cis-retinoic acid

1996 ◽  
Vol 7 (7) ◽  
pp. 800-804 ◽  
Author(s):  
Surintip Piamsomboon ◽  
Wichai Termrungruanglert ◽  
Andrzej P Kudelka ◽  
Creighton L Edwards ◽  
Ralph S Freedman ◽  
...  
Keyword(s):  
Retinoic Acid ◽  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Cell Cancer ◽  
Interferon Α ◽  
Cancer Of The Cervix

Phase III Trial Comparing Radical Radiotherapy With and Without Cisplatin Chemotherapy in Patients With Advanced Squamous Cell Cancer of the Cervix

2002 ◽  
Vol 20 (4) ◽  
pp. 966-972 ◽  
Author(s):  
R. Pearcey ◽  
M. Brundage ◽  
P. Drouin ◽  
J. Jeffrey ◽  
D. Johnston ◽  
...  
Keyword(s):  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Cell Cancer ◽  
Survival Rates ◽  
Progression Free Survival ◽  
Lymph Node Involvement ◽  
Phase Iii ◽  
Gynecology And Obstetrics ◽  
Significant Difference ◽  
Cancer Of The Cervix

PURPOSE: To test the hypothesis that cisplatin (CDDP) administered concurrently with standard radiotherapy (RT) would improve pelvic control and survival in patients with advanced squamous cell cancer of the cervix. PATIENTS AND METHODS: A total of 259 patients with International Federation of Gynecology and Obstetrics stage IB to IVA squamous cell cervical cancer with central disease ≥ 5 cm or histologically confirmed pelvic lymph node involvement were randomized to receive RT (external-beam RT plus brachytherapy) plus weekly CDDP chemotherapy (40 mg/m2) (arm 1) or the same RT without chemotherapy (arm 2). RESULTS: A total of 253 patients were available for analysis. Median follow-up was 82 months. No significant difference was found in progression-free survival (P = .33). No significant difference in 3- and 5-year survival rates was found (69% v 66% and 62% v 58%, respectively; P = .42). The hazard ratio for survival (arm 2 to arm 1) was 1.10 (95% confidence interval, 0.75 to 1.62). CONCLUSION: This study did not show a benefit to either pelvic control or survival by adding concurrent weekly CDDP chemotherapy in a dose of 40 mg/m2 to radical RT as given in this trial. Careful attention to RT details is important for achieving optimum outcome for patients with this disease.

Phase II randomized trial of cisplatin chemotherapy regimens in the treatment of recurrent or metastatic squamous cell cancer of the cervix: a Southwest Oncology Group Study.

1987 ◽  
Vol 5 (11) ◽  
pp. 1791-1795 ◽  
Author(s):  
D S Alberts ◽  
R Kronmal ◽  
L H Baker ◽  
D L Stock-Novack ◽  
E A Surwit ◽  
...  
Keyword(s):  
Randomized Trial ◽  
Mitomycin C ◽  
Phase Ii ◽  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Cell Cancer ◽  
Response Rates ◽  
Oncology Group ◽  
Southwest Oncology Group ◽  
Cancer Of The Cervix

Cisplatin has proven to be the most active single agent in the treatment of metastatic and recurrent squamous cell cancer of the cervix. In a previous southwest Oncology Group (SWOG) pilot study, the addition of cisplatin to a mitomycin-C, vincristine, and bleomycin (MVB) regimen resulted in a relatively high percentage of durable complete responses. To gain more experience with cisplatin-based chemotherapy regimens, the SWOG initiated a phase II randomized trial of cisplatin, mitomycin-C plus cisplatin (MC), and MVB plus cisplatin (MVBC) in 119 patients with advanced squamous cell cancer of the cervix and no prior chemotherapy exposure. Because of slow patient accrual early in the trial, the cisplatin arm was discontinued. Five patients were declared ineligible according to protocol criteria. The three treatment groups were relatively well matched for age, prior radiation exposure, and sites of measurable disease. The overall objective response rates for cisplatin, MC, and MVBC treated patients were 33%, 25%, and 22%, respectively. Median response durations were greater than 6 months. Median survival durations associated with cisplatin, MC, and MVBC treatment were 17.0, 7.0, and 6.9 months, respectively. There were no drug-related deaths. Severe or life-threatening leukopenia and thrombocytopenia were observed in 18% to 24% of patients treated with MVBC and MC, but in none of those receiving cisplatin alone. We conclude that the low response rates and short durations of both response and survival observed in patients randomized to the two chemotherapy combinations suggest that only enhanced toxicity was gained through the addition of mitomycin-C or MVB to cisplatin in patients with advanced cervix cancer.

scholarly journals Clinical features and histological types of 35 cases of carcinoma esophagus: experience from two hospitals in Bangladesh

2017 ◽  
Vol 11 (2) ◽  
pp. 36-39
Author(s):  
Md Nazmul Hoque ◽  
Md Forhadul Islam Chowdhury ◽  
Shireen Ahmed ◽  
Md Abdullah Al Mamoon
Keyword(s):  
Esophageal Cancer ◽  
Clinical Features ◽  
Squamous Cell ◽  
Cell Cancer ◽  
Betel Nut ◽  
Elderly Male ◽  
Cross Sectional ◽  
Histological Types ◽  
History Of ◽  
Carcinoma Esophagus

Background and objectives: Esophageal malignancy is a fatal disease. Squamous cell cancer and adenocarcinoma are two most common types. The present study aimed to describe demographic characteristics, clinical features, histological types and associated among the selected Bangladeshi patients with esophageal cancers.Methods: This cross-sectional descriptive study was conducted from January to December 2016 at two hospitals in Bangladesh. Total 35 adult patients diagnosed as having esophageal cancer were consecutively and purposively included in this study. Age, gender, history of chewing betel nut and smoking, clinical presentation and laboratory parameters were recorded systematically in a predesigned data sheet.Results: Among the 35 patients with esophageal cancer, 80% were more than 50 yrs of age while 71.4% and 28.6% were male and female respectively. Out of these cases, 27 (77.1%) had squamous cell carcinoma (SCC) and 8 (22.9%) had adenocarcinoma. Out of 27 SCC, 15 (55.6%) had lesion in mid-esophagus, 9 (33.3%) in lower and 3 (11.1%) in upper esophagus. All adenocarcinoma were present in lower esophagus. History of smoking and chewing betel nut were not significantly associated with esophageal cancers.Conclusions: Esophageal carcinoma was common in elderly male and SCC was more frequent compared to adenocarcinoma. Further study with larger number of samples is required to determine the role of smoking and betel nut chewing in esophageal cancers in Bangladeshi population.IMC J Med Sci 2017; 11(2): 36-39

Highly Differentiated Keratinizing Squamous Cell Cancer of the Cervix

2001 ◽  
Vol 25 (10) ◽  
pp. 1310-1315 ◽  
Author(s):  
Carl Morrison ◽  
Francesco Catania ◽  
Paul Wakely ◽  
Gerard J. Nuovo
Keyword(s):  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Cell Cancer ◽  
Cancer Of The Cervix
Sign in / Sign up

Export Citation Format

Share Document